Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: Potential relevance to atherosclerotic plaque stability

Atherosclerosis

Volumn 174, Issue 1, 2004, Pages 93-98

  Furman, Christophe ^a   Copin, Corinne ^a   Kandoussi, Mejid ^a   Davidson, Robert ^b   Moreau, Martine ^c   McTaggiart, Fergus ^b   Chapman, M John ^c   Fruchart, Jean Charles ^a   Rouis, Mustapha ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

^b ASTRAZENECA   (United Kingdom)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

HMDM; human monocyte derived macrophages; Macrophages; matrix metalloproteinase; MMP; MMPs; Pleiotropic; Statin; TIMP; tissue inhibitor of metalloproteinase

Indexed keywords

ACETIC ACID; DACTINOMYCIN; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; ISOPRENOID; LUCIFERASE; MATRILYSIN; MESSENGER RNA; ROSUVASTATIN; STATIN;

5' UNTRANSLATED REGION; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME INHIBITION; ENZYME RELEASE; GENE CONSTRUCT; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; MACROPHAGE; MONOCYTE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REPORTER GENE; STEROL SYNTHESIS;

ARTERIOSCLEROSIS; BASE SEQUENCE; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUOROBENZENES; HUMANS; MACROPHAGES; MATRIX METALLOPROTEINASE 7; MOLECULAR SEQUENCE DATA; MONOCYTES; POLYMERASE CHAIN REACTION; PYRIMIDINES; REFERENCE VALUES; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; SULFONAMIDES;

EID: 2342536907     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2004.01.009     Document Type: Article

References (47)

1. Ross R. Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 340:1999;115-126
2. Davies M.J., Thomas A.C. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis characteristic of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br. Heart J. 53:1985;363-373
3. Moreno M.J., Falk E., Palacios I.F., et al. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation. 90:1994;775-778
4. Lendon C.L., Davies M.J., Born G.V.R., Richardson P.D. Atherosclerotic plaque caps are locally weakened when macrophage density is increased. Atherosclerosis. 87:1991;87-90
5. Galis Z., Muszynski M., Sukhova G., et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ. Res. 75:1994;181-189
6. Sakai N., Santamarina-Fojo S., Yamashita S., Matsuzawa Y., Brewer H.B. Exon 10 skipping caused by intron 10 splice donor site mutation in cholesteryl ester transfer protein gene results in abnormal downstream splice selection. J. Lipid Res. 37:1996;2065-2073
7. Galis Z., Sukhova G., Lark M., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94:1994;2493-2503
8. Halpert I., Sires U.I., Roby J.D., et al. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc. Natl. Acad. Sci. U.S.A. 93:1996;9748-9753
9. Galis Z., Sukhova G., Kranzhöfer R., Clark S., Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc. Natl. Acad. Sci. U.S.A. 92:1995;402-406
10. Rajavashisth T.B. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques. Evidence for activation by proinflammatory mediators. Circulation. 99:1999;3103-3109
11. Vaughan C.J., Murphy M.B., Buckley B.M. Statins do more than just lower cholesterol. Lancet. 348:1996;1079-1082
12. Guijarro C., Egido J. Modulation of the mevalonate pathway: potential mechanisms of vascular protection independent of cholesterol reduction. Cardiovasc. Risk Factors. 7:1997;29-33
13. Son J.W., Koh K.K., Ahn J.Y., et al. Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease. Int. J. Cardiol. 88:2003;77-82
14. Koh K.K., Son J.W., Ahn J.Y., et al. Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 22:2002;e19-e23
15. Bellosta S. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis. 137(Suppl.):1998;S101-S109
16. Bernini F., Didoni G., Bonfadini G., Bellosta S., Fumagalli R. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages. Atherosclerosis. 104:1993;19-26
17. Essig M. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ. Res. 83:1998;683-690
18. Colli S. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler. Thromb. Vasc. Biol. 17:1997;265-272
19. Bellosta S., Via D., Canavesi M., et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler. Thromb. Vasc. Biol. 18:1998;1671-1678
20. Ikeda U., Shimpo M., Ohki R., et al. Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells. Hypertension. 36:2000;325-329
21. Wong B., Lumma W.C., Smith A.M., et al. Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. J. Leukoc. Biol. 69:2001;959-962
22. Crisby M., Nordin-Fredriksson G., Shah P.K., et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 103:2001;926-933
23. Aikawa M., Rabkin E., Sugiyama S., et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation. 103:2001;276-283
24. Fukumoto Y., Libby P., Rabkin E., et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation. 103:2001;993-999
25. Nagashima H., Aoka Y., Sakomura Y., et al. A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J. Vasc. Surg. 36:2002;158-163
26. Porter K.E., Naik J., Turner N.A., et al. Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J. Vasc. Surg. 36:2002;150-157
27. Porter K.E., Turner N.A. Statins for the prevention of vein graft stenosis: a role for inhibition of matrix metalloproteinase-9. Biochem. Soc. Trans. 30:2002;120-126
28. Luan Z., Chase A.J., Newby A.C. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler. Thromb. Vasc. Biol. 23:2003;769-775
29. Takeuchi S. Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of Rho GTPase in BAEC. Biochem. Biophys. Res. Commun. 269:2000;97-102
30. Bourcier T., Libby P. HMG-CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler. Thromb. Vasc. Biol. 20:2000;556-562
31. Blasetto J.W., Stein E.A., Brown W.V., Chitra R., Raza A. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am. J. Cardiol. 91:2003;3C-10C. [discussion 10C]
32. Schuster H. Rosuvastatin - a highly effective new 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10-40 mg doses in dyslipidemic patients. Cardiology. 99:2003;126-139
33. Stalker T., Lefer A., Scalia R. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br. J. Pharmacol. 133:2001;406-412
34. Laufs U., Gertz K., Dirnagl U., et al. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischaemic stroke in mice. Brain Res. 942:2002;23-30
35. Taylor-Jones J.M., McGehee R.E., Rando T.A., et al. Activation of an adipogenic program in adult myoblasts with age. Mech. Ageing Dev. 123:2002;649-661
36. de Winther M.P., van Dijk K.W., van Vlijmen B.J., et al. Macrophage specific overexpression of the human macrophage scavenger receptor in transgenic mice, using a 180-kb yeast artificial chromosome, leads to enhanced foam cell formation of isolated peritoneal macrophages. Atherosclerosis. 147:1999;339-347
37. Dentan C., Lesnik P., Chapman M.J., Ninio E. Phagocytic activation induces formation of platelet-activating factor in human monocyte-derived macrophages and in macrophage-derived foam cells. Relevance to the inflammatory reaction in atherogenesis. Eur. J. Biochem. 236:1996;48-55
38. Gaire M., Magbanua Z., McDonnell S., et al. Structure and expression of the human gene for the matrix metalloproteinase matrilysin. J. Biol. Chem. 269:1994;2032-2040
39. Bellosta S. Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care. 23(Suppl.):2000;B72-B78
40. Bienzle D., Abrams-Ogg A.C., Kruth S.A., et al. Gene transfer into hematopoietic stem cells: long-term maintenance of in vitro activated progenitors without marrow ablation. Proc. Natl. Acad. Sci. U.S.A. 91:1994;350-354
41. Brown M.S., Goldstein J.L. Atherosclerosis. Scavenging for receptors. Nature. 343:1990;508-509
42. Casey P.J. Protein lipidation in cell signaling. Science. 268:1995;221-225
43. Seabra M.C., Brown M.S., Goldstein J.L. Retinal degeneration in choroidermia: deficiency of rab geranylgeranyl transferase. Science. 259:1993;377-381
44. Bond M., Baker A.H., Newby A.C. Nuclear factor κB activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts. Biochem. Biophys. Res. Commun. 264:1999;561-567
45. Chase A.J., Bond M., Crook M.F., Newby A.C. Role of nuclear factor-κB activation in metalloproteinase-1, -3, and -9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo. Arterioscler. Thromb. Vasc. Biol. 22:2002;765
46. Brown P.D., Bloxidge R.E., Anderson E., Howell A. Expression of activated gelatinase in human invasive breast carcinoma. Clin. Exp. Metastasis. 11:1993;183-189
47. Zempo N., Koyama N., Kenagy R.D., Lea H.J., Clowes A.W. Regulation of vascular smooth muscle cell migration and proliferation in vitro and injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler. Thromb. Vasc. Biol. 16:1996;28-33